Condensed Consolidated Statements of Changes in Equity (unaudited) - USD ($) $ in Millions	Total	Total Baxter stockholders' equity	Common stock	Common stock in treasury	Additional contributed capital	Retained earnings	Accumulated other comprehensive income (loss)	Noncontrolling interests
Balance, beginning of period (in shares) at Dec. 31, 2024			683,000,000
Balance, beginning of period (in usd) at Dec. 31, 2024	$ 7,024	$ 6,964	$ 683	$ (11,059)	$ 6,421	$ 14,929	$ (4,010)	$ 60
Balance, treasury, beginning period (in shares) at Dec. 31, 2024				173,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	126	126				126		0
Other comprehensive income (loss)	(47)	(47)					(47)	0
Stock issued under employee benefit plans and other (in shares)				(3,000,000)
Stock issued under employee benefit plans and other	10	10		$ 122	(112)
Dividends declared on common stock	(87)	(87)				(87)
Reclassification of other comprehensive income (loss) disposed in the Kidney Care separation	115	115					115
Disposition of noncontrolling interest associated with the Kidney Care separation	(87)							(87)
Balance, end of period (in shares) at Mar. 31, 2025			683,000,000
Balance, end of period (in usd) at Mar. 31, 2025	7,054	7,081	$ 683	$ (10,937)	6,309	14,968	(3,942)	(27)
Balance, treasury, ending period (in shares) at Mar. 31, 2025				170,000,000
Balance, beginning of period (in shares) at Dec. 31, 2025			683,000,000
Balance, beginning of period (in usd) at Dec. 31, 2025	$ 6,102	6,129	$ 683	$ (10,873)	6,368	13,705	(3,754)	(27)
Balance, treasury, beginning period (in shares) at Dec. 31, 2025	169,213,617			169,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ (15)	(15)				(15)		0
Other comprehensive income (loss)	(48)	(48)					(48)
Stock issued under employee benefit plans and other (in shares)				(2,000,000)
Stock issued under employee benefit plans and other	(18)	(18)		$ 136	(154)
Dividends declared on common stock	(5)	(5)				(5)
Balance, end of period (in shares) at Mar. 31, 2026			683,000,000
Balance, end of period (in usd) at Mar. 31, 2026	$ 6,016	$ 6,043	$ 683	$ (10,737)	$ 6,214	$ 13,685	$ (3,802)	$ (27)
Balance, treasury, ending period (in shares) at Mar. 31, 2026	167,047,900			167,000,000